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Causal Pathways from Blood 
Pressure to Larger QRS Amplitudes: 
a Mendelian Randomization Study
M. Yldau Van Der Ende  1, Tom Hendriks1, Dirk J. Van Veldhuisen1, Harold Snieder2,  
Niek Verweij  1 & Pim Van Der Harst  1
Abnormal QRS duration and amplitudes on the electrocardiogram are indicative of cardiac pathology 
and are associated with adverse outcomes. The causal nature of these associations remains uncertain 
and could be due to QRS abnormalities being a symptom of cardiac damage rather than a factor 
on the causal pathway. By performing Mendelian randomization (MR) analyses using summary 
statistics of genome wide association study consortia with sample sizes between 20,687 and 339,224 
individuals, we aimed to determine which cardiovascular risk factors causally lead to changes in 
QRS duration and amplitude (Sokolow-Lyon, Cornell and 12-leadsum products). Additionally, we 
aimed to determine whether QRS traits have a causal relationship with mortality and longevity. We 
performed inverse-variance weighted MR as main analyses and MR-Egger regression and weighted 
median estimation as sensitivity analyses. We found evidence for a causal relationship between higher 
blood pressure and larger QRS amplitudes (systolic blood pressure on Cornell: 55SNPs, causal effect 
estimate per 1 mmHg = 9.77 millimeters·milliseconds (SE = 1.38,P = 1.20 × 10−12) and diastolic blood 
pressure on Cornell: 57SNPs, causal effect estimate per 1 mmHg = 14.89 millimeters·milliseconds 
(SE = 1.82,P = 3.08 × 10−16), but not QRS duration. Genetically predicted QRS traits were not 
associated with longevity, suggesting a more prominent role of acquired factors in explaining the well-
known link between QRS abnormalities and outcome.
A central feature of the electrocardiogram (ECG) is the QRS complex, reflecting ventricular depolarization. 
Abnormalities in the duration and amplitudes of the QRS complex are indicative of (early) cardiac pathology, 
including disorders of the conduction system and cardiac hypertrophy1–3. Abnormal QRS duration and ampli-
tudes have also been associated with an increased risk of cardiovascular events and mortality3–10. The causal 
nature of these associations remains uncertain and changes in QRS duration and amplitudes could be a symptom 
of cardiac damage or a factor on the causal pathway. In this study, we aimed to determine which cardiovascular 
risk factors causally lead to QRS changes (Fig. 1A). Additionally, we aimed to determine whether a causal rela-
tionship of genetically predicted QRS traits with mortality and longevity exists (Fig. 1B). Mendelian randomization 
(MR) analyses are designed to investigate the causal nature of the relationship between risk factors and outcomes 
in observational data in the presence of confounding factors11. Using genetic variants as instruments, which are 
randomly assigned when passed from parents to offspring during meiosis, the genotype distribution in the pop-
ulation should be unrelated to the presence of confounders. To date, no such approach has been used to study the 
causal influence of risk factors on QRS abnormalities on the one hand and the influence of genetically predicted 
variation in QRS duration and amplitudes on mortality and longevity on the other hand. We recently conducted 
a large meta-analysis of genome wide association studies (GWAS) for QRS duration and amplitude yielding 52 
loci for these traits (n = 73,518, explaining 2.7%, 3.2%, 4.1% and 5.0% of the variance of Sokolow-Lyon, Cornell, 
12-lead sum and QRS duration, respectively)12. The summary statistics of this GWAS meta-analysis were used as 
outcome (cardiovascular risk factors on QRS traits) or exposure (QRS traits on mortality and longevity) in our 
MR analyses.
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Results
Association between cardiovascular risk factors and QRS traits. Genetic variants for QRS duration 
and amplitude were extracted from the summary statistics of a large-scale GWAS and replication study of these 
phenotypes12. Table 1 and Supplementary Table 1 provide overviews of the combined effects of genetic variants 
previously associated with cardiovascular risk factors and their association with QRS duration and amplitude. 
Genetically predicted higher systolic blood pressure was associated with larger QRS amplitudes (Sokolow-Lyon 
(β 15.21, SE 2.38); Cornell (β = 9.77, SE = 1.38) and 12-lead sum (β = 86.35, SE = 12.45)) but not QRS duration. 
Also, genetically predicted higher diastolic blood pressure was associated with larger QRS amplitudes (Sokolow-
Lyon (β = 23.20, SE = 3.76); Cornell (β = 14.89, = SE 1.82) and 12-lead sum (β = 111.28, SE = 18.81), but again 
not with QRS duration. The displayed β’s are in millimeters·milliseconds units. Figures 2 and 3 display the forest 
and scatter plots of systolic and diastolic blood pressure with ECG Cornell criteria, since these associations were 
most significant. The weighted median estimate confirmed the results. The MR Egger intercepts for analyses 
between blood pressure and QRS amplitudes were within the confidence interval of zero (P-values > 0.10), except 
from diastolic blood pressure on Cornell product. Searching for known pleiotropic effects of the blood pressure 
associated variants in the GWAS catalogue yielded little already known pleiotropic loci. In total, nine systolic or 
diastolic blood pressure loci had pleiotropic effects on other traits (loci in FURIN-FES associated with myocar-
dial infarction, TMEM26-AS1 with Takotsubo, SH2B3 with white blood cells, SLE39A8 with body mass index 
and ZNF318-ABCC10 and ZC3HC1 with platelet count, ULK4 with multiple myeloma, BAT2-BAD5 with colitis 
ulcerosa and MDM4 with breast cancer). Excluding these loci from our analyses did not change the significance. 
Because the heterogeneity P-values for the associations between blood pressure and amplitudes (except from 
diastolic blood pressure on Cornell product) were all smaller than 0.05 the analyses were repeated without the 
individually significant genetic variants (Supplementary files, Table 2 and Figs 1–5), after which heterogeneity 
P-values were all above 0.705. All of the associations between genetically predicted blood pressure and QRS 
Figure 1. Flow charts of the MR analyses performed. (A) Is the schematic presentation of the MR analyses of 
cardiovascular risk factors on QRS traits to determine which cardiovascular risk factors causally lead to changes 
in QRS duration and QRS amplitude. (B) Is the schematic presentation of the MR analyses of QRS traits on 
mortality and longevity to determine whether a causal relationship of QRS traits with mortality and longevity 
exists.
Risk 








QRS duration 1.60 × 10−2
Sokolow-Lyon 1.73 × 10−10 15.21 (2.38) 2.59 × 10−9 13.69 (2.28) 0.44 (4.05) 0.914 1.74 × 10−13
Cornell 1.20 × 10−12 9.77 (1.38) 8.56 × 10−10 9.01 (1.47) 0.30 (2.34) 0.900 3.97 × 10−5
12-lead sum 3.99 × 10−12 86.35 (12.45) 6.69 × 10−14 89.02 (11.88) −5.15 (21.19) 0.809 1.95 × 10−13
DBP
QRS duration 4.33 × 10−2
Sokolow-Lyon 6.96 × 10−10 23.20 (3.76) 2.19 × 10−12 26.26 (3.74) 1.08 (4.28) 0.801 1.82 × 10−11
Cornell 3.08 × 10−16 14.89 (1.82) 1.93 × 10−10 15.50 (2.43) −4.38 (1.99) 0.032 1.07 × 10−1
12-lead sum 3.28 × 10−9 111.28 (18.81) 1.78 × 10−10 121.89 (19.11) −15.52 (21.31) 0.470 1.61 × 10−9
Table 1. Mendelian Randomization analyses of cardiovascular risk factors and QRS traits. β = beta (in 
millimeters·milliseconds); DBP = Diastolic Blood Pressure; SBP = Systolic Blood Pressure; SE = Standard Error.
www.nature.com/scientificreports/
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amplitudes remained significant after exclusion of these individually significant genetic variants. The estimated 
statistical power for our MR analyses of blood pressure on QRS amplitudes were all above 0.80. No other associ-
ations between cardiovascular risk factors (measures of obesity, lipids and glucose levels, diabetes and smoking) 
and QRS traits were identified (P-values > 9.62 × 10−5, Supplementary Table 1).
Association between QRS traits and mortality and longevity. MR analyses were performed to 
determine the association of QRS duration and amplitudes with mortality and longevity. Genetic and follow-up 
data of 143,193 participants of the UK Biobank was available. During a median follow-up of 6.9 years (IQR 6.3–
7.6 years), 4,372 participants died, of which 2,653 due to a cardiovascular cause. None of the genetically predicted 
QRS traits were associated with all-cause mortality or cardiovascular mortality (Supplementary file, Table 3). MR 
analyses between QRS traits and longevity also provided no evidence of association (Supplementary file, Table 3). 
We performed further sensitivity analyses by adding additional instrumental variables with higher P-values (up 
Figure 2. Forest plots: SBP and DBP associated with ECG Cornell criteria. On the X-axis the Mendelian 
Randomization effect size of blood pressure on Cornell product were displayed. On de Y-axis the different 
genetic variants were listed. DBP = diastolic blood pressure, MR = Mendelian randomization, SBP = systolic 
blood pressure.
Figure 3. Scatter plots: SBP and DBP associated with ECG Cornell criteria. On the X-axis the variant effects on 
blood pressure are displayed and on the Y-axis the variant effect on Cornell product. The light blue line is the 
regression line of the inverse-variance-weighted fixed-effects meta analyses. The dark blue line is the regression 
line of the MR Egger regression line. DBP = diastolic blood pressure, MR = Mendelian randomization, 
SBP = systolic blood pressure.
www.nature.com/scientificreports/
4SCiENTifiC REPORTS | (2018) 8:5817 | DOI:10.1038/s41598-018-24002-0
to P < 1 × 10−4) for QRS-traits to the MR analyses but this did not change the observations (Supplementary file, 
Table 3). The estimated statistical power for the MR analyses of QRS traits on mortality was below 0.80 for all QRS 
traits, but the estimated statistical power for the MR analyses of QRS traits on longevity was always above 0.80.
Discussion
We found evidence for a causal relationship between higher systolic and diastolic blood pressure and larger QRS 
amplitudes (Sokolow-Lyon, Cornell and 12-lead sum products) but not QRS duration. No associations between 
other cardiovascular risk factors and QRS traits were found. Genetically predicted QRS traits were not associated 
with longevity. Our analyses of QRS traits on mortality were underpowered and could be repeated when more 
follow-up data of the UK Biobank will be available. In traditional population-based cohort studies, multiple 
associations between cardiovascular risk factors and larger QRS amplitudes and duration have been established, 
but whether these associations are causal is less clear. By studying the genotypes affecting blood pressure, we 
established evidence for a causal relationship of blood pressure with larger QRS amplitudes, but not with an 
increase in QRS duration. Larger QRS amplitudes are possibly more directly related to cardiac mass in response 
to increased blood pressure compared to QRS duration. Blood pressure and larger QRS amplitude and duration 
have been associated in multiple studies investigating the phenotype of blood pressure13–16. The difficulty is that 
the well-established relationship between higher blood pressure and QRS duration reported earlier may not be 
causal and might be a consequence of confounding factors both affecting blood pressure and QRS duration. For 
example, body mass index, both affecting blood pressure as well as QRS amplitudes17. In this study, we now found 
evidence for a causal relationship. In our MR analyses, no other cardiovascular risk factors (measures of obesity, 
lipids and glucose levels, diabetes and smoking) were associated with QRS duration or amplitudes, suggesting 
the absence of a direct causal relationship. Associations between the phenotypes of body mass index, diabetes 
and smoking with ventricular hypertrophy have well been described18,19. These observed links might be due 
to acquired or confounding risk factors or could very well be driven by the clustering of these risk factors with 
hypertension, since less than 20% of hypertension occurs without the presence of another cardiovascular risk 
factor20. Additionally, measured QRS amplitudes in individuals with a high body mass index will be lower due to 
increased chest wall and pericardial fat mass17, making it more difficult to detect signs of ventricular hypertro-
phy on ECG. One limitation of our MR approach is that the variants used were derived from a GWAS on QRS 
duration and amplitudes which was adjusted for body mass index12, possibly explaining the absence of associ-
ations between genetically predicted body mass index and QRS traits. In our study, genetically predicted QRS 
traits were not associated with longevity in the general population. Phenotypes of QRS duration and amplitude 
are well-known predictors of cardiovascular disease and mortality21–25, but a direct causal relationship has not 
been described and could be confounded by other factors. Additionally, no attempt has been made to differenti-
ate between the effects of primary versus secondary QRS abnormalities. Our findings suggest that the reported 
association between QRS traits and mortality (in populations with medical conditions) may indeed have resulted 
more from the (confounding) environmental risk factors than the genetic component of QRS duration and ampli-
tudes itself. Further, associations between QRS traits and mortality or longevity could very well be driven by 
extreme cases (such as QRS duration > 120 ms) that fall out of range of the genetically predicted variation.
Some general limitations of our MR analyses should be considered as these rely on three key assumptions. 
First, the genetic variants must associate with the risk factor of interest. Second, the genetic variants may not 
associate with potential confounders. Third, the genetic variants may only affect the outcome via the risk factor of 
interest11. To be a valid instrumental variable, a genetic variant should be associated only with the respective risk 
factor. The genetic variants used in our analyses were genome wide significant associated with the risk factors and 
by calculating F-statistics for the genetic variants we demonstrated that our analyses were unlikely to be biased 
due to weak instruments. For systolic and diastolic blood pressure, there is an overlap of the genetic variants (19 
variants), which make it more difficult to discriminate the instrumental variants of systolic blood pressure and 
diastolic blood pressure correctly from each other. Excluding these genetic variants from our analyses would lead 
to a loss of strength of our MR analyses. By performing sensitivity analyses for pleiotropy and heterogeneity, we 
were able to reduce the risk of pleiotropy and heterogeneity. By performing weighed median estimates and MR 
Egger regressions we tested for pleiotropic bias. We also searched for known pleiotropic effects and performed 
Cochran’s Q tests to examine heterogeneity. The sensitivity analyses provided supporting evidence for a causal 
association between high blood pressure and QRS amplitudes. Another limitation is that for some cardiovascular 
risk factors (e.g. cigarettes smoked per day and fasting insulin), the instrumental variables do not explain a large 
proportion of the variation in these traits. Identifying more genetic variants associated with these risk factors 
will lead to more statistical power to find causal associations between these risk factors and QRS traits, resulting 
in a lower probability of finding false negative results. Also, in the MR analyses, unmeasured confounders may 
be involved. Therefore, a limitation of the current study is that we cannot entirely rule out that our analyses are 
unbiased from any (unmeasured) confounder. The GWAS meta-analyses results used for our MR analyses were 
based on genetic associations test including possible confounders. For example, the meta-analysis of GWAS on 
QRS traits was tested including age, gender, height and body mass index as covariates12. Additionally, the genetic 
variants associated with cardiovascular risk factors, QRS traits and mortality and longevity were obtained in 
predominantly Caucasians, minimizing the possibility of population stratification bias, but also limit our study to 
Caucasians and our results are therefore not generalizable to other ethnicities. Finally, since we exclusively used 
genetic variants of published GWAS with complete information on the effect size (β) with standard error (SE) 
and effect and non-effect allele of each variant, we could not use the most recent GWAS publications for some of 
the cardiovascular risk factors. Adding more variants to our analyses may have improved the risk predictions and 
statistical power.
www.nature.com/scientificreports/
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Conclusion
High blood pressure likely causes larger QRS amplitudes on the ECG. Genetically predicted larger QRS dura-
tion and amplitudes in the general population are not linked to longevity, suggesting a more prominent role of 
acquired factors explaining the phenotypic link between QRS abnormalities and outcome.
Methods
Study design. Our study design consisted of two stages. 1) First, we identified genetic variants associated 
with cardiovascular risk factors (blood pressure, body mass index, lipids and diabetes and smoking) in previously 
published GWAS data (Supplementary Tables 4–16). 2) We applied these genetic predictors of cardiovascular risk 
factors (instrumental variables for the exposure traits) to a large-scale GWAS of QRS traits (the Sokolow-Lyon, 
Cornell, and 12-lead-voltage (12-leadsum) duration products and QRS duration) to determine which cardiovas-
cular risk factors might lead causally to QRS changes (Fig. 1A). This GWAS meta-analysis was performed in up 
to 73,518 individuals of European ancestry from 24 studies with 12-lead ECG data12. The mean age of the partic-
ipants included in the individual studies of this GWAS meta-analysis ranged from 39 to 76 years. The percentage 
of women included in the individual studies ranged from 0% to 95%.
Subsequently, we used the genetic variants associated with QRS traits as instrumental variables in MR anal-
yses to determine whether a causal relationship exist between genetically predicted QRS traits and mortality and 
longevity (outcome, Fig. 1B).
Identification of genetic variants associated with cardiovascular risk factors. Genetic variants 
genome-wide significantly (P < 5 × 10−8) associated with cardiovascular risk factors were obtained from previ-
ously published summary statistics of GWAS (Table 2), filtered on P value and clumped on linkage disequilibrium 
using the MR base R package using default settings (https://mrcieu.github.io/TwoSampleMR/). We exclusively 
used GWAS datasets with complete information on the effect size (β) with standard error (SE), effect and 
non-effect allele of each variant and the variance explained (R2) by the genetic variants. To ensure the strength 
of the instruments, we generated F-statistics for these genetic variants (Table 2). The F-statistics were calculated 
using the formula [R2 × (n − 1 − K)]/[(1 − R2) × K], in which R2 represents the proportion of variability of each 
cardiovascular risk factor that is explained by the genetic variants, n represents sample size, and K represents the 
number of IVs included in the model. An F-value above ten indicates that a causal estimate is unlikely to be biased 
due to weak instruments26. For each cardiovascular risk factor variant, we determined the effect of these variants 
on the QRS traits in the abovementioned raw GWAS meta-analysis data12. All variants per cardiovascular risk fac-
tor and their effects on these risk factors and effect and non-effect allele are listed in Supplementary Tables 4–16. 
Before MR analyses were performed, the exposure data (variant on risk factor) and outcome data (variant on QRS 
trait) were harmonized to guarantee that the effect corresponded to the same allele. Summary statistics between 
exposures and outcomes were harmonized in R using the MR-base package using default settings. Genetic vari-
ants were discarded from analysis if alleles did not correspond for the same genetic variant. In case of palindromic 
genetic variants (if alleles on the forward strand are the same as on the reverse strand), outcome effects were 
flipped if the alleles on the reverse strand did not correspond to alleles on the forward strand based on the effect 
allele frequency (if the allele frequency was above 0.42, genetic variants were discarded).




range)** Ancestry R2 (%) F-statistics Pubmed ID
Systolic Blood pressure 74 European cohorts 55 mmHg 201,529 21.5–75.6 0.0–77.2 European 3.4 2588.6 27618452
30
Diastolic blood pressure 74 European cohorts 57 mmHg 201,529 21.5–75.6 0.0–77.2 European 3.5 2667.5 27618452
30
HDL cholesterol GLGC 89 SD 187,167 21.5–75.0 0.0–69.6 European 1.6 1196.4 2409706831
LDL cholesterol GLGC 80 SD 173,082 21.5–75.0 0.0–69.6 European 2.4 1808.8 2409706831
Triglycerides GLGC 54 SD 177,861 21.5–75.0 0.0–69.6 European 2.1 1578.0 2409706831
Total cholesterol GLGC 88 SD 187,365 21.5–75.0 0.0–69.6 European 2.6 1963.5 2409706831
Fasting glucose MAGIC 35 mmol/L 133,010 11.5–75.7 0.0–71.3 European 4.8 3707.8 2288592432
Fasting Insulin MAGIC 14 Log pmol/L 108,557 11.5–75.7 0.0–71.3 European 1.2 893.9 2288592432
Body mass index GIANT 79 SD 339,224 18.9–75.7 0.0–100.0 European 2.7 2041.1 2567341333
Waist Hip Ratio adjusted 
Body mass index GIANT 31 SD 224,459 18.9–75.3 0.0–100.0 European 1.4 1044.9 25673412
34
Apolipoprotein A-I 14 European cohorts 11 SD 20,687 23.9–60.9 37.0–60.0 European 5.0 3870.4 27005778
35
Apolipoprotein B 14 European cohorts 21 SD 20,690 23.9–60.9 37.0–60.0 European 8.6 6918.5 27005778
35
Cigarettes smoked per day TAG 1 Cigarettes per day 68,028 39.6–72.3 11.6–100 European 0.5 370.4 20418890
36
Table 2. SNPs associated with cardiovascular risk factors. HDL = High Density Lipoprotein; LDL = Low 
Density Lipoprotein. *Range of the mean age of the participants included in the individual studies of the GWAS 
meta-analysis. **Range of the percentage of women included in the individual studies of the GWAS meta-
analysis.
www.nature.com/scientificreports/
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Mendelian randomization analyses. To determine the effect of cardiovascular risk factors on QRS traits, 
inverse-variance-weighted (MR-IVW) fixed-effects meta analyses were performed, as described before11. The 
cardiovascular risk factors were considered as the exposures and the QRS traits as the outcomes (Fig. 1A). Units 
of the cardiovascular risk factors for which MR analyses were scaled are listed in Table 2. For the MR analyses, we 
considered a multiple testing (Bonferroni-corrected) P-value < 9.62 × 10−5 (0.005/(13 risk factors x 4 QRS traits)) 
as statistically significant27.
To determine the effect (β) of genetic variants associated with QRS traits on mortality, MR-IVW analyses 
were performed in which the QRS traits were considered as exposures and mortality and (parental) longevity as 
outcomes (Fig. 1B). To determine the effect of the genetic variants associated with QRS traits on mortality, cox 
regression analyses on mortality with these genetic variants (P < 1 × 10−8) were performed in all participants 
with genetic information of the UK Biobank (N = 143,193). For the analyses of longevity, previously published 
summary statistics of GWAS on longevity were used as outcome data28. Longevity was defined as combined 
mothers and fathers age at death. For sensitivity purposes, we attempted to increase power of the instruments by 
adding genetic variants with higher P-values for QRS traits (P < 1 × 10−7, <1 × 10−6, <1 × 10−5 & <1 × 10−4) and 
repeated the MR analyses.
To explore pleiotropy or heterogeneity of our effect estimates, we evaluated weighted median estimate, MR 
Egger regression and Cochran’s Q test. The weighed median estimate and MR Egger regressions were performed 
to test for pleiotropic bias. Where the MR-IVW method assumes absence of pleiotropic effects for all included 
genetic variants, the weighted median estimation allows that up to 50% of the weight of genetic variants comes 
from invalid instruments29. The MR Egger regression method allows all the instrumental variables to be invalid, 
and is therefore less powerful than the weighted median estimate29. The estimated value of the intercept in Egger 
regression can be interpreted as an estimate of the average pleiotropic effect across the genetic variants, since the 
intercept will differ from zero when the estimates from small studies are more skewed towards either high or 
low values compared to large studies11. P-value and the intercept (including SE) with the Y-axis were reported. 
P-values < 0.10 of the Egger’s intercept were considered to provide evidence for pleiotropic bias. In addition, we 
performed heterogeneity statistics using the Cochran’s Q test and reported the heterogeneity P-value. A heter-
ogeneity P-value < 0.05 was considered to provide evidence of heterogeneity, in which case MR analyses were 
repeated without the instrumental variables that were individually associated (P < 0.05) with QRS traits. Power 
calculations were carried out using the online tool http://cnsgenomics.com/shiny/mRnd/. The power could not 
be calculated directly as different units were used for the different traits and only summary statistics were availa-
ble. Therefore, we estimated the statistical power for the MR analyses of blood pressure on QRS traits and of QRS 
traits on mortality and longevity using standardized values. These standardizes values (z-scores) were calculated 
using the mean and standard deviations of these variables. In the UK Biobank dataset, the minimum detectable 
odds ratio between genetically predicted QRS traits and mortality was estimated at 1.25 per standard deviation 
of the QRS traits. The minimum detectable effect for an association between genetically predicted QRS traits and 
longevity (in years) was estimated at β = 0.1 per standard deviation of the QRS traits.
Forest plots were constructed for adjusted effects of instrumental variables on QRS duration and amplitude if 
specific cardiovascular risk factors were associated with QRS traits. Scatterplots and trend lines (MR Egger and 
IVW) were plotted to provide insights into the individual instrumental variable effects on QRS duration and 
amplitude compared to the effects sizes of the cardiovascular risk factors. All MR analyses were performed using 
R version 3.3.2.
Data availability. The genetic data associated with cardiovascular risk factors analysed during this study 
are included in this published article and its Supplementary Information files. The genetic data associated with 
QRS traits or longevity are available as summary statistics online. The dataset of mortality is available from the 
corresponding author on reasonable request.
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